Jan Stetka

Olomouc, Czech Republic

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

A single JAK2-V617F hematopoietic stem cell can initiate myeloproliferative neoplasm when transplanted into non-conditioned recipient mice.

A single JAK2-V617F hematopoietic stem cell can initiate myeloproliferative neoplasm when transplanted into non-conditioned recipient mice.

Journal: HemaSphere
Published: June 09, 2025

Loss of Socs2 improves molecular responses to IFNα in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F.

Loss of Socs2 improves molecular responses to IFNα in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F.

Journal: Leukemia
Published: June 10, 2024

The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN.

The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN.

Journal: Blood advances
Published: June 12, 2023

Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms.

Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms.

Journal: Blood
Published: March 06, 2023

Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms.

Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms.

Journal: HemaSphere
Published: December 07, 2022

Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms.

Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms.

Journal: Blood
Published: August 01, 2022

Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients.

Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients.

Journal: Cancers
Published: March 30, 2021

Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents.

Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents.

Journal: Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
Published: December 14, 2020

Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes.

Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes.

Journal: Cancers
Published: March 13, 2020

JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality.

JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality.

Journal: Blood
Published: February 28, 2020

Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation.

Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation.

Journal: Oncogene
Published: February 10, 2019

Effect of 9-cis retinoic acid and all-trans retinoic acid in combination with verapamil on P-glycoprotein expression in L1210 cells.

Effect of 9-cis retinoic acid and all-trans retinoic acid in combination with verapamil on P-glycoprotein expression in L1210 cells.

Journal: Neoplasma
Published: July 18, 2014
Showing 1-12 of 12

Last Updated: 09/26/2026